CA3204202A1 - Cyclobenzaprine treatment for fibromyalgia - Google Patents
Cyclobenzaprine treatment for fibromyalgiaInfo
- Publication number
- CA3204202A1 CA3204202A1 CA3204202A CA3204202A CA3204202A1 CA 3204202 A1 CA3204202 A1 CA 3204202A1 CA 3204202 A CA3204202 A CA 3204202A CA 3204202 A CA3204202 A CA 3204202A CA 3204202 A1 CA3204202 A1 CA 3204202A1
- Authority
- CA
- Canada
- Prior art keywords
- cyclobenzaprine
- mannitol
- eutectic
- composition
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063122469P | 2020-12-07 | 2020-12-07 | |
| US63/122,469 | 2020-12-07 | ||
| PCT/US2021/062244 WO2022125572A1 (en) | 2020-12-07 | 2021-12-07 | Cyclobenzaprine treatment for fibromyalgia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3204202A1 true CA3204202A1 (en) | 2022-06-16 |
Family
ID=79686930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3204202A Pending CA3204202A1 (en) | 2020-12-07 | 2021-12-07 | Cyclobenzaprine treatment for fibromyalgia |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20240024256A1 (https=) |
| EP (1) | EP4255407A1 (https=) |
| JP (1) | JP2023554692A (https=) |
| CN (1) | CN116940340A (https=) |
| AU (1) | AU2021396509A1 (https=) |
| CA (1) | CA3204202A1 (https=) |
| IL (1) | IL303497A (https=) |
| MX (1) | MX2023006720A (https=) |
| WO (1) | WO2022125572A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3260042A1 (en) * | 2022-06-21 | 2023-12-28 | Tonix Pharmaceuticals Holding Corp. | CYCLOBENZAPRINE TREATMENT FOR POST-ACUTE SEQUELAE OF A (SARS)-COV-2 (PASC) INFECTION |
| WO2025137348A1 (en) * | 2023-12-19 | 2025-06-26 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine hcl for use in treating fibromyalgia with early onset response and favorable tolerability and side effect profile |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS63822B1 (sr) | 2012-06-15 | 2023-01-31 | Tonix Pharma Holdings Ltd | Kompozicije i postupci za transmukoznu apsorpciju |
| SMT202400324T1 (it) | 2013-03-15 | 2024-11-15 | Tonix Pharma Ltd | Formulazioni eutettiche di ciclobenzaprina cloridrato e mannitolo |
| MY186047A (en) * | 2014-09-18 | 2021-06-17 | Tonix Pharma Holdings Ltd | Eutectic formulations of cyclobenzaprine hydrochloride |
| US20220117915A1 (en) * | 2018-08-20 | 2022-04-21 | Tonix Pharma Holdings Limited | Methods of treating acute stress disorder and posttraumatic stress disorder |
-
2021
- 2021-12-07 US US18/265,525 patent/US20240024256A1/en active Pending
- 2021-12-07 EP EP21844438.8A patent/EP4255407A1/en active Pending
- 2021-12-07 IL IL303497A patent/IL303497A/en unknown
- 2021-12-07 MX MX2023006720A patent/MX2023006720A/es unknown
- 2021-12-07 JP JP2023542924A patent/JP2023554692A/ja active Pending
- 2021-12-07 AU AU2021396509A patent/AU2021396509A1/en active Pending
- 2021-12-07 CN CN202180089897.8A patent/CN116940340A/zh active Pending
- 2021-12-07 WO PCT/US2021/062244 patent/WO2022125572A1/en not_active Ceased
- 2021-12-07 CA CA3204202A patent/CA3204202A1/en active Pending
-
2025
- 2025-12-16 US US19/421,039 patent/US20260108477A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021396509A1 (en) | 2023-06-29 |
| WO2022125572A1 (en) | 2022-06-16 |
| CN116940340A (zh) | 2023-10-24 |
| EP4255407A1 (en) | 2023-10-11 |
| US20240024256A1 (en) | 2024-01-25 |
| JP2023554692A (ja) | 2023-12-28 |
| MX2023006720A (es) | 2023-08-18 |
| IL303497A (en) | 2023-08-01 |
| US20260108477A1 (en) | 2026-04-23 |
| AU2021396509A9 (en) | 2024-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260108477A1 (en) | Cyclobenzaprine treatment for fibromyalgia | |
| CN101772346B (zh) | 用于降低治疗副作用的方法和组合物 | |
| EP2135610A1 (en) | Combination comprising DHODH inhibitors and methotrexate | |
| EA006384B1 (ru) | Композиция фентанила для интраназального введения | |
| CA2434484A1 (en) | Compositions comprising ibuprofen and diphenhydramine to treat pain-associated sleep disturbances | |
| JP2021080276A (ja) | デクスメデトミジン製剤を使用する睡眠障害の予防または治療 | |
| SK14612003A3 (sk) | Použitie enantiomérne čistého escitalopramu a farmaceutický prostriedok s obsahom escitalopramu | |
| TW202019400A (zh) | 治療急性壓力症候群及創傷後壓力症候群之方法 | |
| KR20250167147A (ko) | 이명, 급성 감각신경성 난청, 메니에르병, 투렛 증후군, 주의력 결핍 과잉행동 장애 및 중독의 치료에 있어서 (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 시클로펜탄-1-카르복시산 및 (s)-3-아미노-4-(디플루오로메틸리덴)시클로펜트-1-엔-1-카르복시산의 용도 | |
| CA2993614A1 (en) | Combination therapy using acamprosate and d-cycloserine | |
| JP2013510187A (ja) | 誘発されたジスキネジアを治療又は予防するためのキセノンベースの吸入可能薬物 | |
| EA008768B1 (ru) | Композиция для улучшения познавательной способности и памяти | |
| KR20020015329A (ko) | 멜라토닌의 치료학적 용도 | |
| MXPA02003519A (es) | Composicion oralmente desintegrante que comprende mirtazapina. | |
| HK40102591A (zh) | 纤维肌痛的环苯紮林治疗 | |
| JP2006508118A5 (https=) | ||
| KR20040068327A (ko) | 임상적 우울증 치료를 위한 디옥시페가닌의 용도 | |
| US20250322926A1 (en) | Early onset response, favorable tolerability, and side effect profile in the treatment of fibromyalgia | |
| EP3200793A1 (en) | Atropine sulfate rapidly-disintegrating sublingual tablets, methods for manufacture, and methods for use thereof for treatment of acute organophosphate toxicity | |
| KR102671524B1 (ko) | 구역 반사의 치료를 위한 조성물 및 요법 | |
| RU2468813C1 (ru) | Средство для профилактики или лечения острых и хронических нарушений мозгового кровообращения, применение и способ лечения | |
| US20190247296A1 (en) | Atropine sulfate rapidly-disintegrating sublingual tablets of improved formulation, methods for manufacture thereof, and methods for use thereof for treatment of acute organophosphate toxicity | |
| Yadav et al. | Concise review: Therapeutic potential of flupirtine maleate | |
| Tetrud | Balancing short-term symptom control and long-term functional outcomes in patients with Parkinson's disease | |
| Vo et al. | Guidelines for the Use of Parkinsonian Drugs (in USA) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241122 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241122 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241122 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251205 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251205 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251205 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251212 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251212 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260119 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260203 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260203 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260203 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260205 |